Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018

IMPORTANCE: The growth of cancer drug spending in the US has outpaced spending in nearly all other sectors, and an increasing proportion of the drug development pipeline is devoted to oncology. In 2018, there was a record number of drugs entering the US market. OBJECTIVE: To estimate the number of p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Archives of internal medicine (1960) 2021-02, Vol.181 (2), p.162-167
Hauptverfasser:	DeMartino, Patrick C, Miljkovic, Miloš D, Prasad, Vinay
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - economics Cancer Cost control Drug Approval - economics Drug delivery systems Drug development FDA approval Humans Medical Oncology Neoplasms - drug therapy Oncology Online First Original Investigation Patients Retrospective Studies United States United States Food and Drug Administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!